Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GAMMA: Ganitumab + Gemcitabine in Metastatic Pancreatic Cancer
NCT01231347Phase 3Completed
- Sponsor
- ImmunityBio, Inc.
- Start
- Apr 2011
- Primary completion
- Dec 2012
- Modality
- Monoclonal Antibodies
- Countries
- 32
01
Overview
Phase 3, randomised, double-blind trial of ganitumab in pancreatic adenocarcinoma (PDAC) (3 arms), sponsored by ImmunityBio, Inc. Primary endpoint: Overall Survival at 20 months. Started Apr 2011; status: completed.
02
Drugs
ganitumab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT01231347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01231347.